GSK Acquires Nuvalent for $10.6 Billion

Pharmaceutical powerhouse GSK has unveiled its most significant acquisition in eight years, agreeing to purchase US cancer drug firm Nuvalent for a staggering $10.6 billion.

This strategic move is designed to substantially bolster GSK's oncology portfolio, with a particular focus on expanding its offerings in the lung cancer treatment sector.

The acquisition is expected to enhance GSK's research and development capabilities, bringing new innovative therapies to market.

This major investment underscores GSK's commitment to becoming a leader in cancer treatment and addressing unmet medical needs globally.